MX2017005195A - Composicion farmaceutica para uso en el aumento del trofismo de mucosa nasal. - Google Patents

Composicion farmaceutica para uso en el aumento del trofismo de mucosa nasal.

Info

Publication number
MX2017005195A
MX2017005195A MX2017005195A MX2017005195A MX2017005195A MX 2017005195 A MX2017005195 A MX 2017005195A MX 2017005195 A MX2017005195 A MX 2017005195A MX 2017005195 A MX2017005195 A MX 2017005195A MX 2017005195 A MX2017005195 A MX 2017005195A
Authority
MX
Mexico
Prior art keywords
nasal mucosa
trophism
increase
pharmaceutical composition
nasal
Prior art date
Application number
MX2017005195A
Other languages
English (en)
Other versions
MX372726B (es
Inventor
Guerra Germano
Testa Domenico
Panin Giorgio
Original Assignee
Bio Lo Ga Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51951918&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017005195(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bio Lo Ga Srl filed Critical Bio Lo Ga Srl
Publication of MX2017005195A publication Critical patent/MX2017005195A/es
Publication of MX372726B publication Critical patent/MX372726B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Otolaryngology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composición para aplicación tópica, para uso en el incremento de trofismo de la mucosa nasal, que comprende un éster de vitamina E con un ácido carboxílico de la fórmula RCOOH, en la cual R es un radical alquilo que tiene 1 a 19 átomos de carbono, o un radical alquenilo o alquinilo que tiene 2 a 19 átomos de carbono, y un vehículo aceitoso; esta composición se puede utilizar para el tratamiento de rinitis atrófica crónica y para obtener la reparación de tejido de la mucosa nasal después de la cirugía nasal y de senos paranasales.
MX2017005195A 2014-10-22 2015-10-02 Composicion farmaceutica para uso en el aumento del trofismo de mucosa nasal MX372726B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI20141819 2014-10-22
PCT/EP2015/072796 WO2016062522A1 (en) 2014-10-22 2015-10-02 Pharmaceutical composition for use in increasing the trophism of nasal mucosa

Publications (2)

Publication Number Publication Date
MX2017005195A true MX2017005195A (es) 2017-10-04
MX372726B MX372726B (es) 2020-05-06

Family

ID=51951918

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017005195A MX372726B (es) 2014-10-22 2015-10-02 Composicion farmaceutica para uso en el aumento del trofismo de mucosa nasal

Country Status (21)

Country Link
US (1) US10226444B2 (es)
EP (1) EP3209294B1 (es)
CN (1) CN107438429A (es)
AU (1) AU2015335204B2 (es)
CA (1) CA2965184A1 (es)
CL (1) CL2017000971A1 (es)
CY (1) CY1122289T1 (es)
DK (1) DK3209294T3 (es)
EA (1) EA033078B1 (es)
ES (1) ES2757349T3 (es)
GE (2) GEP20186863B (es)
HR (1) HRP20191989T1 (es)
HU (1) HUE047203T2 (es)
LT (1) LT3209294T (es)
MX (1) MX372726B (es)
PL (1) PL3209294T3 (es)
PT (1) PT3209294T (es)
RS (1) RS59496B1 (es)
SI (1) SI3209294T1 (es)
SM (1) SMT201900592T1 (es)
WO (1) WO2016062522A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3468530A4 (en) 2016-06-10 2020-03-11 Clarity Cosmetics Inc. NON-COMEDOGEN FORMULA FOR HAIR AND SCALP CARE AND METHOD FOR USE
IT201700047210A1 (it) 2017-05-02 2018-11-02 St Ganassini Spa Di Ricerche Biochimiche Composizione cosmetica e/o dermatologica, e suoi usi in campo cosmetico e nel trattamento coadiuvante di patologie dermatologiche
IT201900003515A1 (it) * 2019-03-11 2020-09-11 Gilas Sas Di Carcano Maria Grazia E C COMPOSIZIONE DERMO-COSMETICA PER USO TOPICO, A BASE DI VITAMINA E e/o SUOI ESTERI
IT202100013898A1 (it) * 2021-05-27 2022-11-27 Hulka S R L Composizione comprendente un estere di alfa-tocoferolo per la riduzione del rischio di parto pretermine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4364945A (en) 1979-12-13 1982-12-21 Whittle Barry J Nasal composition for relieving nasal distress
US20100055152A1 (en) 2008-08-26 2010-03-04 Trutek Corporation Antihistamine and antihistamine-like nasal application, products, and method
IT1282778B1 (it) 1996-05-31 1998-03-31 Giorgio Panin Vitamina "e" acetato quale prodotto per applicazione topica
ITMI981586A1 (it) * 1998-07-10 2000-01-10 Giorgio Panin Vitamina e e suoi esteri per l'uso nel trattamento topico di patologie delle mucose
IT1393056B1 (it) * 2008-09-22 2012-04-11 Bio Lo Ga Srl Uso di vitamina e o suoi derivati per il controllo di artropodi
US10561720B2 (en) 2011-06-24 2020-02-18 EpitoGenesis, Inc. Pharmaceutical compositions, comprising a combination of select carriers, vitamins, tannins and flavonoids as antigen-specific immuno-modulators
FR2981273B1 (fr) * 2011-10-14 2013-12-20 Gilles Andre Yves Bhat Nouvelle composition pour les muqueuses: tocopherol, macerat huileux de fleurs de calendula dans de l'huile de rose musquee, palmitate de retinol, ubiquinone, ascorbyl palmitate et lactobacillus

Also Published As

Publication number Publication date
CN107438429A (zh) 2017-12-05
US10226444B2 (en) 2019-03-12
EP3209294B1 (en) 2019-08-21
AU2015335204B2 (en) 2020-10-08
LT3209294T (lt) 2019-10-25
BR112017008070A2 (pt) 2018-02-20
WO2016062522A1 (en) 2016-04-28
GEP20186863B (en) 2018-06-11
PL3209294T3 (pl) 2020-01-31
GEAP201814463A (en) 2018-02-26
CY1122289T1 (el) 2021-01-27
SMT201900592T1 (it) 2019-11-13
US20170290799A1 (en) 2017-10-12
HUE047203T2 (hu) 2020-04-28
CA2965184A1 (en) 2016-04-28
EP3209294A1 (en) 2017-08-30
CL2017000971A1 (es) 2018-01-12
HRP20191989T1 (hr) 2020-02-07
AU2015335204A1 (en) 2017-04-13
DK3209294T3 (da) 2019-10-28
MX372726B (es) 2020-05-06
SI3209294T1 (sl) 2019-12-31
EA201790447A1 (ru) 2017-09-29
PT3209294T (pt) 2019-10-08
BR112017008070A8 (pt) 2022-07-05
ES2757349T3 (es) 2020-04-29
EA033078B1 (ru) 2019-08-30
RS59496B1 (sr) 2019-12-31

Similar Documents

Publication Publication Date Title
MX2025003983A (es) Nanoparticulas lipidicas mejoradas para el suministro de acidos nucleicos
ECSP19010079A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
PE20170904A1 (es) Esteroides neuroactivos, composiciones y usos de los mismos
CL2017001893A1 (es) Uso de prg4 como agente antiinflamatorio
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
MX2020004209A (es) Composiciones y metodos para modular la expresion de la apolipoproteina c-iii.
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
MX2016007658A (es) Composiciones basadas en metil ciclodextrinas para el tratamiento y/o prevencion de enfermedades aumentando el nivel de colesterol hdl.
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
DOP2013000239A (es) Derivados de ácido 3-fenilpropiónico ramificados y su uso.
CY1122289T1 (el) Φαρμακευτικη συνθεση για χρηση στην αυξηση του τροφισμου της ρινικης βλεννογονου
CU20150091A7 (es) Estra-1, 3,5(10), 16tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3)
BR112016012840A2 (pt) Derivado de pirimidina e fonte de ácido graxo para uso no tratamento de prisão de ventre
BR112015024332A2 (pt) sonda fluorescente para estanho
MX2016015437A (es) Combinacion que comprende un glucocorticoide y edo-s101.
CL2018001221A1 (es) Modular la expresión de apolipoproteína (a)
BR112015022162A2 (pt) sonda fluorescente de zinco
CL2016001192A1 (es) Uso de un inhibidor de dihidroorato deshidrogenasa (dhodh) para tratar enfermedades neurodegenerativas.
CL2012003006A1 (es) Compuestos derivados de lactonas esteroideas insaturadas en la posicion 7(8) y sus sales y estereoisomeros farmaceuticamente aceptables; composicion farmaceutica que las comprende; y su uso para el tratamiento del cancer.
PE20151669A1 (es) Compuestos de azetidiniloxifenilpirrolidina
BR112015014262A8 (pt) formulação farmacêutica, dispositivo adaptado para distribuição intranasal de uma formulação farmacêutica, e, uso de uma formulação farmacêutica
CL2015001502A1 (es) Composición farmacéutica que comprende desloratadina y prendnisolona y uso de la misma.
CL2015003460A1 (es) Composiciones oftálmicas acuosas tópicas que contienen un derivado de 1h-indol-1-carboxamida y uso de estas para el tratamiento de una enfermedad oftálmica
CL2019003254A1 (es) Formulación basada en vitamina e o un éster de la misma para tratar biopelículas bacterianas y fúngicas.
BR112015025101A2 (pt) composição antitumoral que compreende um inibidor pi3kbeta-seletivo e um inibidor pi3kalfa-seletivo

Legal Events

Date Code Title Description
FG Grant or registration
PD Change of proprietorship

Owner name: HULKA S.R.L.